M I L D C O G N I T I V E impairment (MCI) is a diagnostic entity u s e d t o d e s c r i b e defective memory
performances that do not fulfill the criteria for dementia. 1 Mild cognitive impairment includes incipient Alzheimer disease (AD) and other causes of dementia, as well as a form of cognitive impairment that does not progress to dementia and may disappear. This entity has been redefined to include amnesic MCI (aMCI) and nonamnesic MCI, according to the presence of an isolated objective memory deficit or of multiple or isolated extramemory cognitive impairment. 2 This variation in MCI has been evaluated using neuroimaging [3] [4] [5] and biologic markers. 6, 7 Results of clinical studies 5, 8 have suggested that neuropsychological tests, especially those evaluating delayed recall, might play an important role in identifying early or preclinical AD among subjects with MCI. These studies, however, were conducted among small groups of subjects.
Herein, we report data from a clinical and positron emission tomography with fluodeoxyglucose F 18 ( 18 FDG-PET) assessment within a large multicenter study of subjects with aMCI. The objectives of this study were to evaluate whether 18 FDG-PET can differentiate subjects with aMCI from healthy control subjects, to assess functional metabolic patterns in aMCI that might predict different clinical progressions, and to investigate the role of combining Author Affiliations are listed at the end of this article. 18 FDG-PET findings and memory scores in predicting conversion to AD at the individual level.
METHODS

SUBJECTS
Sixty-seven right-handed subjects with aMCI (34 men and 33 women; mean±SD age, 67.7±8.4 years) and 41 healthy controls (18 men and 23 women; mean±SD age, 59.6±5.7 years) were enrolled in the study. They were selected at 4 participating centers enrolled in the Network for Efficiency and Standardization of Dementia Diagnosis Fifth European Framework Research Project. The research was approved by the local ethics committees, and all participants provided written informed consent. The controls were interviewed and assessed for cognitive dysfunction.
All subjects underwent a somatic and neurologic examination, routine laboratory tests, a multidimensional neuropsychological assessment, a brain structural imaging study (computed tomography or magnetic resonance imaging), and an 18 FDG-PET scan. Amnesic MCI was diagnosed using to the Mayo Clinic criteria. 1 Behavioral disorders and depression were excluded by the Neuropsychiatric Inventory 9 and by the Hamilton Depression Rating Scale. 10 Forty-eight subjects with aMCI were followed up every 6 to 7 months for at least 1 year (median follow-up, 12 months; follow-up range, 12-27 months). At follow-up, subjects were diagnosed as having stable aMCI (aMCI nonconverters) or as having converted to AD (aMCI converters) on the basis of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria.
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NEUROPSYCHOLOGICAL ASSESSMENT
The global severity of cognitive impairment was measured by the Mini-Mental State Examination 12 and by the Washington University Clinical Dementia Rating scale. 13 All patients underwent the extensive neuropsychological Network for Efficiency and Standardization of Dementia Diagnosis battery (Table) . 14 The California Verbal Learning Test (CVLT) 15 was administered at all participating centers, and long-term memory was assessed by different methods at the centers. The test results provided an in-depth evaluation of memory to assess the diagnosis of aMCI.
FDG-PET DATA ACQUISITION AND IMAGE PREPROCESSING
Studies were performed according to previously described methods. 16 The software packages SPM99 (Wellcome Department of Cognitive Neurology, University College, London, England) and MATLAB 6.1 (MathWorks Inc, Sherborn, Mass) were used for image preprocessing. Images were spatially normalized to a reference stereotactic template (Montreal Neurological Institute, McGill University, Montreal, Quebec) by a 12-parameter transformation and smoothed by a Gaussian kernel of 12ϫ12ϫ12-mm voxels full width at half maximum. 16, 17 
STATISTICAL ANALYSIS
Statistical Parametric Mapping
Voxel-by-voxel statistical parametric mapping of 18 FDG radioactivity distribution images was performed using SPM99. Global differences in the distribution of the tracer's uptake and age effect were covaried out for all voxels. 17 Comparisons across the different groups were made using t statistics with appropriate linear contrasts.
Volumes of Interest and Receiver Operating Characteristic Curves
Analysis of volumes of interest (VOIs) and receiver operating characteristic (ROC) curves was aimed at evaluating whether CVLT-Long Delay Free Recall (CVLT-LDFR) scores and 18 FDG-PET findings might be useful in predicting progression to AD at the individual level. The hypometabolic regions of aMCI converters vs controls, obtained by SPM99 analysis at PϽ.001, were used to define VOIs. Considering only clusters exceeding 700 voxels, 3 VOIs in the temporoparietal regions and posterior cingulate cortex were selected. The regionalsensorimotor 18 FDG uptake ratio (regional cerebral glucose metabolism ratio [rCGM-r]) was considered in the analysis. To discriminate among groups, ROC curve analysis was performed on CVLT-LDFR scores (score range, 0-16) and on the rCGM-r.
Kaplan-Meier Estimates
We used R software (available at: http://www.r-project.org) to perform Kaplan-Meier analysis of survival to estimate the conversion to AD among the aMCI subgroups in the presence of censored data (aMCI nonconversion and unequal follow-up time to assess conversion). The curves were compared using the logrank test.
RESULTS
CLINICAL FINDINGS
Demographic and clinical characteristics of the study group are given in the Table. As expected, subjects with aMCI had impaired performances (−1.5 SDs compared with the control data) only on tests of verbal and nonverbal long-term memory.
Forty-eight (71.6%) of 67 subjects with aMCI completed the clinical and neuropsychological follow-up examination. Fourteen (29.2%) of the 48 developed AD and were classified as aMCI converters. Thirty-four (70.8%) of the 48 remained stable and were classified as aMCI nonconverters. Among the 67 subjects, there were 19 dropouts (28.4%) (Table) .
Baseline long-term memory scores were significantly lower among aMCI converters compared with aMCI nonconverters, and aMCI converters had CVLT-LDFR scores indicating more severe impairment (score range, 0-6), while aMCI nonconverters had scores that were evenly distributed (Figure 1) . Visuospatial abilities and executive functions, even if within normal ranges, were more impaired among aMCI converters than aMCI nonconverters (Table) .
DISCRIMINANT ROC CURVE ANALYSIS
Discriminant ROC curve analysis was performed among the 48 subjects who completed the follow-up. First, the 
ratios (rCGM-r). California Verbal Learning Test-Long Delay Free
Recall scores of 7 or higher accurately predict stable aMCI, while the rCGM-r can discriminate the outcome in subjects with CVLT-LDR scores less than 7. Circles indicate aMCI nonconverters; diamonds, aMCI converters; the 3 ringed symbols, subjects with a misdiagnosis. ROC curve calculated for CVLT-LDFR scores demonstrated an area under the curve of 0.783. The ROC curve analysis indicated a sensitivity of 96.8%, corresponding to a specificity of 58.8% at a CVLT-LDFR score of 7. At this level, the negative predictive value (the likelihood that the subject is healthy) was 95.2%, while the positive predictive value (the likelihood that the subject will develop AD) was 48.1%. A CVLT-LDFR score of 7 or higher discriminated all the aMCI nonconverters except 1; a CVLT-LDFR score less than 7 had too little power for establishing the risk of progression to AD (Figure 1 ). Therefore, we defined 2 subgroups, subjects with lower CVLT-LDFR scores, ranging from 0 to 6, and subjects with higher CVLT-LDFR scores, ranging from 7 to 16. Second, the ROC curve calculated for the rCGM-r, measured in the temporoparietal and posterior cingulate VOIs, demonstrated an area under the curve of 0.863. At an rCGM-r of 1.138, the sensitivity was 92.9%, the specificity was 82.4%, the negative predictive value was 96.55%, and the positive predictive value was 68.4%.
Third, with regard to CVLT-LDFR scores less than 7, the rCGM-r of 1.138 had a positive predictive value of 92.3%, a negative predictive value of 92.8%, a sensitivity of 92.3%, a specificity of 92.8%, and an area under the curve of 0.879.
Fourth, the combined use of a CVLT-LDFR score of 7 and the rCGM-r of 1.138 had a sensitivity of 85.7%, a specificity of 97.1%, a positive predictive value of 92.3%, and a negative predictive value of 94.3%. Results of the Kaplan-Meier analysis showed a risk of conversion to AD that was significantly different among subjects with aMCI based on CVLT-LDFR score (PϽ.01) or rCGM-r (PϽ.001) (Figure 2) .
SPM FINDINGS aMCI Converters vs aMCI Nonconverters
Among aMCI converters compared with controls, 18 No pixels exceeding the threshold were detected by the opposite comparison that is between the group with CVLT-LDFR scores 7 or higher and the group with scores 6 or lower.
COMMENT
Improved characterization of MCI features may aid in identifying subjects with incipient but asymptomatic AD. 2, 18 Among a large group of subjects with aMCI, our study differentiated these subjects from controls, and we demonstrated 18 FDG-PET metabolic heterogeneity among the subjects with aMCI. One year before the onset of AD, aMCI converters showed the typical AD functional pattern, with hypometabolism in the parietal and posterior cingulate cortex. 16 Among aMCI nonconverters, hypometabolism was confined to the dorsolateral frontal cortex.
In addition, 18 FDG-PET metabolic heterogeneity was associated with different severities of memory impairment, as assessed by CVLT-LDFR scores. Severe memory impairment with an AD metabolic pattern is associated with a high risk of short-term conversion to dementia. In contrast, subjects with less memory impairment without conversion to AD show a frontal metabolic pattern. Memory impairment in aMCI nonconverters might be ascribed to the dorsolateral frontal hypometabolism. Prefrontal structures are known to be involved in episodic memory processes such as encoding and retrieval. 19, 20 These functional data parallel and strengthen the results of a previous large multicenter clinical study 18 that demonstrated successful implementation of operational criteria in the evaluation of aMCI.
The combined use of CVLT-LDFR scores and 18 FDG uptake in selected VOIs, as shown by the ROC curve analysis, seems to be a promising tool for predicting outcomes among individual subjects with aMCI. When considering only CVLT-LDFR scores, we demonstrated a low probability of converting to AD (4.8%) among patients with milder long-term memory deficit, and we found high probabilities of converting to AD (48.1%) or of maintaining aMCI (51.9%) among subjects with more severe memory impairment. Therefore, among subjects with severe memory impairment, 18 FDG-PET findings were crucial in predicting which subjects would rapidly develop dementia. Indeed, the mean levels of 18 FDG uptake measured in selected VOIs correctly classified 92.3% of aMCI converters and 92.8% of aMCI nonconverters. Although conversion to AD is time dependent and subjects with aMCI were followed up for variable intervals (follow-up range, 12-27 months), the Kaplan-Meier analysis showed that the differences observed in this study are not due to censored data.
Our findings have implications for clinical practice. This study supports the view that the present criteria for aMCI define a heterogeneous population whose degree of memory impairment correlates with different patterns of brain functional involvement and possibly with different pathologic substrates. Therefore, proposed criteria for aMCI may apply to a heterogeneous population in which reports of memory loss could be due to somatic diseases, drug-induced states, affective disorders, or other neurologic conditions, rather than an ongoing AD-related process. 21 Longer follow-up is needed to estimate the clinical outcome of subjects with a frontal hypometabolic pattern of aMCI. 
